Checkmate Pharmaceuticals, Inc. (CMPI) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
245 MAIN STREET, 2ND FLOOR CAMBRIDGE, MA 02142 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2022 MRQ | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments, including: | 70,900,000 | 125,900,000 | |||
| Cash and cash equivalents | 50,675,000 | 43,055,000 | |||
| Short-term investments | 20,192,000 | ||||
| Other undisclosed cash, cash equivalents, and short-term investments | 33,000 | 82,845,000 | |||
| Restricted cash and investments | 20,000 | 20,000 | |||
| Other undisclosed current assets | 3,042,000 | (23,819,000) | |||
| Total current assets: | 73,962,000 | 102,101,000 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 777,000 | ||||
| Long-term investments and receivables | 30,973,000 | ||||
| Long-term investments | 30,973,000 | ||||
| Other noncurrent assets | 4,099,000 | ||||
| Total noncurrent assets: | 4,876,000 | 30,973,000 | |||
| TOTAL ASSETS: | 78,838,000 | 133,074,000 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,379,000 | 7,875,000 | |||
| Accounts payable | 3,385,000 | 2,297,000 | |||
| Accrued liabilities | 5,994,000 | 5,578,000 | |||
| Total current liabilities: | 9,379,000 | 7,875,000 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 9,379,000 | 7,875,000 | |||
| Equity | |||||
| Equity, attributable to parent | 69,459,000 | 125,199,000 | |||
| Common stock | 2,000 | 2,000 | |||
| Additional paid in capital | 270,947,000 | 265,342,000 | |||
| Accumulated other comprehensive loss | (14,000) | (74,000) | |||
| Accumulated deficit | (201,476,000) | (140,071,000) | |||
| Total equity: | 69,459,000 | 125,199,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 78,838,000 | 133,074,000 | |||
Income Statement (P&L) (USD)
| 3/31/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Operating expenses | (61,470,000) | (36,904,000) | ||
| Operating loss: | (61,470,000) | (36,904,000) | ||
| Nonoperating income (expense) | 65,000 | (4,000) | ||
| Investment income, nonoperating | 100,000 | 79,000 | ||
| Loss from continuing operations: | (61,405,000) | (36,908,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (61,405,000) | (36,908,000) | |
| Net loss attributable to parent: | (61,405,000) | (36,908,000) | ||
| Preferred stock dividends and other adjustments | (5,997,000) | |||
| Net loss available to common stockholders, diluted: | (61,405,000) | (42,905,000) | ||
Comprehensive Income (USD)
| 3/31/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Net loss: | (61,405,000) | (36,908,000) | ||
| Comprehensive loss: | (61,405,000) | (36,908,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 60,000 | (74,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (61,345,000) | (36,982,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.